Regenxbio said its Duchenne muscular dystrophy gene therapy RGX-202 cleared a key bar in a pivotal study, setting up an FDA submission process aimed at commercializing a new option for a market with limited therapies. The company framed the milestone around achieving sufficient levels of a miniaturized muscle protein tied to the therapeutic payload, positioning the data for regulatory review under accelerated pathways. Separately, BeOne Medicines won a US accelerated approval for sonrotoclax (Beqalzi) in relapsed or refractory mantle cell lymphoma after prior treatment with a BTK inhibitor. The decision adds a new BCL-2 targeting competitor in a space dominated by venetoclax-style approaches and underscores how quickly oncology developers are moving when biomarker and response signals align. Taken together, the developments highlight two fast-moving tracks in gene and cell therapy and targeted oncology: construction of next regulatory submissions from pivotal datasets, and rapid US approvals in blood cancers where prior-line settings create space for differentiated mechanisms.